Genetic Analysis 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Ronny Hermansen

최고 경영자

NOK 2.0m

총 보상

CEO 급여 비율	93.8%
CEO 임기	no data
CEO 소유권	2.1%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Ronny Hermansen 의 보수는 Genetic Analysis 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-NOK 21m
Jun 30 2024	n/a	n/a	-NOK 22m
Mar 31 2024	n/a	n/a	-NOK 22m
Dec 31 2023	NOK 2m	NOK 2m	-NOK 24m
Sep 30 2023	n/a	n/a	-NOK 25m
Jun 30 2023	n/a	n/a	-NOK 27m
Mar 31 2023	n/a	n/a	-NOK 28m
Dec 31 2022	NOK 2m	NOK 2m	-NOK 28m
Sep 30 2022	n/a	n/a	-NOK 28m
Jun 30 2022	n/a	n/a	-NOK 28m
Mar 31 2022	n/a	n/a	-NOK 29m
Dec 31 2021	NOK 2m	NOK 2m	-NOK 29m
Sep 30 2021	n/a	n/a	-NOK 30m
Jun 30 2021	n/a	n/a	-NOK 27m
Mar 31 2021	n/a	n/a	-NOK 25m
Dec 31 2020	NOK 2m	NOK 2m	-NOK 22m
Dec 31 2019	NOK 2m	NOK 2m	-NOK 7m

보상 대 시장: Ronny 의 총 보상 ($USD 181.40K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 236.30K ).

보상과 수익: Ronny 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Ronny Hermansen (61 yo)

no data

테뉴어

NOK 2,009,312

보상

Mr. Ronny Hermansen, MSc serves as Chief Executive Officer at Genetic Analysis AS. Previously, Mr. Hermansen served as a Finance Director of an Axis-Shield plc since March 2007 subsidiary, Axis-Shield ASA...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Rune Sorum	Director	no data	NOK 125.00k	데이터 없음
Robert Lofberg	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lena Öhman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ole Nielsen	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Gerhard Rogler	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Wolfgang Kruis	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Lars Engstrand	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Morten Vatn	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Anne Camilla Bondesson	Director	4.1yrs	NOK 125.00k	0.33% NOK 72.6k
Andrew Stapleton	Director	2.6yrs	데이터 없음	데이터 없음
Per Matsson	Chairperson	2.6yrs	NOK 400.00k	0.32% NOK 68.9k

2.6yrs

평균 재임 기간

68yo

평균 연령

경험이 풍부한 이사회: GEAN 의 이사회는 경험(평균 재직 기간 2.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Genetic Analysis 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Genetic Analysis as Announces Resignation of Eilert Aamodt as Chief Financial Officer

Genetic Analysis as Announces Resignation of Eilert Aamodt as Chief Financial Officer

Genetic Analysis AS, Annual General Meeting, May 14, 2024

Genetic Analysis AS Announces Resignation of Staffan Strömberg from the Board of Directors

Genetic Analysis AS Announces Changes in Members of Nomination Committee

Genetic Analysis AS, Annual General Meeting, May 11, 2023

Recent updates

New major risk - Share price stability

Third quarter 2024 earnings released: kr0.065 loss per share (vs kr0.17 loss in 3Q 2023)

Genetic Analysis AS to Report Q3, 2024 Results on Nov 15, 2024

Genetic Analysis AS to Report Q2, 2024 Results on Aug 30, 2024

Genetic Analysis as Announces Resignation of Eilert Aamodt as Chief Financial Officer

Genetic Analysis as Announces Resignation of Eilert Aamodt as Chief Financial Officer

First quarter 2024 earnings released: kr0.14 loss per share (vs kr0.29 loss in 1Q 2023)

Genetic Analysis AS to Report Q1, 2024 Results on May 29, 2024

Full year 2023 earnings released: kr0.62 loss per share (vs kr1.13 loss in FY 2022)

Genetic Analysis AS, Annual General Meeting, May 14, 2024

New major risk - Share price stability

Full year 2023 earnings released: kr0.62 loss per share (vs kr1.13 loss in FY 2022)

Genetic Analysis AS to Report Fiscal Year 2023 Results on Feb 29, 2024

Genetic Analysis AS has completed a Follow-on Equity Offering in the amount of NOK 3.235125 million.

New major risk - Shareholder dilution

New major risk - Share price stability

Genetic Analysis AS Provides Earnings Guidance for the Year 2023, 2024, and 2025

Genetic Analysis AS has filed a Follow-on Equity Offering in the amount of NOK 9 million.

Third quarter 2023 earnings released: kr0.17 loss per share (vs kr0.27 loss in 3Q 2022)

Genetic Analysis AS Announces Resignation of Staffan Strömberg from the Board of Directors

Genetic Analysis AS Launches the GA-map® Discovery - New Microbiome Profiling Service Offering Directed to Research Customers in the Academia and Microbiome Industry

Genetic Analysis AS to Report Nine Months, 2023 Results on Nov 16, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.24 loss in 2Q 2022)

Genetic Analysis AS to Report Q2, 2023 Results on Aug 30, 2023

Genetic Analysis AS Announces Changes in Members of Nomination Committee

Forecast breakeven date pushed back to 2025

Consensus revenue estimates fall by 12%

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Genetic Analysis AS, Annual General Meeting, May 11, 2023

Genetic Analysis AS Announces Executive Changes

Genetic Analysis as Achieves Thai Fda License for Ga-Map[®] Dysbiosis Test in Thailand

Genetic Analysis AS to Report Fiscal Year 2022 Results on Feb 17, 2023

No independent directors

Third quarter 2022 earnings released: kr0.27 loss per share (vs kr0.28 loss in 3Q 2021)

Second quarter 2022 earnings released

Genetic Analysis AS Announces Board Changes

No independent directors

Genetic Analysis Strengthens Its Management Team by Hiring Head of Operations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Genetic Analysis as Launches on a New Technology Platform, GA-map® Dysbiosis Test Kit

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령